UCB SA (LON:0NZT)

London flag London · Delayed Price · Currency is GBP · Price in EUR
158.30
+1.72 (1.10%)
At close: Jun 20, 2025
14.18%
Market Cap 27.40B
Revenue (ttm) 5.09B
Net Income (ttm) 880.72M
Shares Out n/a
EPS (ttm) 4.53
PE Ratio 31.11
Forward PE 22.79
Dividend 0.83 (0.52%)
Ex-Dividend Date Apr 25, 2025
Volume 9,442
Average Volume 58,919
Open 159.03
Previous Close 156.58
Day's Range 156.85 - 159.60
52-Week Range 129.35 - 198.70
Beta 0.26
RSI 61.64
Earnings Date Jul 31, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange London Stock Exchange
Ticker Symbol 0NZT
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.